Almost everyone can ignore this — grapefruit is a healthy fruit and St John's wort is a fine herbal antidepressant for people on nothing else. The audience this matters to is anyone on a daily prescription. For that reader the action is two-step and free: open the pillbox, read this article. Five minutes of awareness sits between people and some of the more under-reported drug accidents in modern medicine — transplant rejections, unintended pregnancies, muscle damage that lands you on a drip.
When you swallow a pill, most of the drug doesn't reach your bloodstream untouched. There's an enzyme called CYP3A4 sitting in the wall of your gut and in your liver, and its job is to chew up incoming chemicals before they get far. About half of all prescription drugs pass through it. The dose printed on the bottle is calibrated assuming this enzyme is doing its normal job — chewing up some of the drug, letting some through.
Grapefruit shuts the enzyme down. A glass of juice — even just one — contains chemicals called furanocoumarins that bind to CYP3A4 in your gut wall and permanently disable the individual enzyme molecules they touch. Your body can only fix this by building new enzyme protein from scratch, which takes between one and three days. In the meantime, drugs that should have been broken down at the gut wall now sail through intact. Plasma levels rise to whatever they would have been on a much higher dose.
St John's wort does the opposite, more slowly. Its active ingredient, hyperforin, switches on a master regulator inside liver cells that tells the cell to make more CYP3A4. Over about two weeks of daily dosing the amount of enzyme in your gut and liver climbs noticeably; by a month it is much higher than normal. Drugs that should have lasted a full day in your bloodstream now get chewed up faster than they can do their work. Plasma levels fall toward whatever they would have been on a lower dose, or no dose at all.
Two mirror-image problems, then. Grapefruit: enzyme goes down, drug goes up, you've effectively overdosed on a normal prescription. St John's wort: enzyme goes up, drug goes down, you're effectively unmedicated. Both effects stick around — grapefruit's for days after the last glass, St John's wort's for around two weeks after the last pill.
Which drugs, and how badly
Not every prescription is affected — only the ones CYP3A4 chews up. That list, unfortunately, includes some of the most common drugs in modern medicine. Five classes carry the biggest stakes.
Statins
If you take simvastatin or lovastatin and drink grapefruit juice daily, the level of drug in your blood can go up by a factor of ten or more. Lilja et al. 1998 measured a roughly 16-fold rise in simvastatin plasma levels in healthy volunteers drinking 200 mL of double-strength grapefruit juice three times a day for three days. At those levels, the muscle-damage side effect statins are known for — normally rare — stops being rare. There are case reports in the literature of people on simvastatin who ate grapefruit at breakfast and ended up hospitalised with rhabdomyolysis. Atorvastatin is also affected, though less dramatically Lilja et al. 1999. Pravastatin, rosuvastatin, fluvastatin, and pitavastatin are not — they don't go through CYP3A4. St John's wort moves the dial the other way: it cuts simvastatin and atorvastatin levels, and your LDL number stops budging. And red yeast rice — the cholesterol supplement sold in the health-food aisle — is a low-dose statin in disguise, its active ingredient being lovastatin by another name, so grapefruit drives its levels up exactly the way it does the prescription kind.
Immunosuppressants
This is the corner of the catalogue where the interaction goes from "be careful" to "this has killed people." Cyclosporine and tacrolimus, the drugs that keep transplanted organs from being rejected, have an extremely narrow window between "working" and "not enough." St John's wort drops cyclosporine levels by 30–60%.
Grapefruit pushes cyclosporine and tacrolimus in the other direction — too high, with kidney toxicity and tremor.
Calcium-channel blockers (blood pressure)
The dihydropyridines — felodipine, nifedipine, nisoldipine, amlodipine — are the class where the grapefruit story started. Plasma levels rise two- to ten-fold with regular grapefruit, depending on the specific drug. The felt experience: your blood pressure drops too low, you stand up and the room tilts, your heart pounds in compensation, your ankles swell. Bailey et al. 2013 document several case reports of patients on these drugs who fainted or were hospitalised after starting daily grapefruit. St John's wort works the opposite way — drug level falls, blood pressure creeps back up.
Hormonal contraceptives
The combined contraceptive pill works by keeping a steady level of synthetic estrogen and progestin in your blood. St John's wort speeds the liver's clearance of both. Murphy et al. 2005 ran the definitive trial: 16 women on a low-dose combined pill added St John's wort for one cycle. Hormone levels fell, ovaries woke up, and 2 of the 16 ovulated through the pill — something that's essentially never supposed to happen in a normal cycle. Breakthrough bleeding shot up. Hall et al. 2003 reported similar findings. Unintended pregnancies on the combined pill while taking St John's wort are documented in case reports Schwarz et al. 2003. Grapefruit's effect on the pill is smaller and not associated with contraceptive failure.
Psychotropic drugs
Two separate problems layer on top of each other here. The first is a plasma-level swing — many benzodiazepines (alprazolam, midazolam, triazolam), buspirone, quetiapine, and a long list of antidepressants are CYP3A4 substrates. Grapefruit raises their levels; St John's wort lowers them. The second is more dangerous and has nothing to do with CYP3A4: St John's wort is itself an antidepressant — it acts on the same serotonin system as SSRIs. Combine it with a prescription SSRI, SNRI, MAOI, tramadol, or a triptan migraine pill and you can produce serotonin syndrome — agitation, sweating, racing heart, muscle tremor, sometimes a fever that needs intensive care.
There are other affected classes worth flagging briefly: the newer blood thinners apixaban and rivaroxaban (both directions of swing are dangerous), warfarin (St John's wort drops INR; clot risk rises), HIV antiretrovirals (St John's wort can cause virological failure), and erectile dysfunction drugs (grapefruit potentiates the hypotensive effect). Bailey et al. 2013 catalogue more than 85 drugs with significant grapefruit interactions; the full St John's wort list is similar in length Borrelli & Izzo 2009, Mannel 2004.
What this actually looks like when it goes wrong
The patterns repeat. They don't look like a drug interaction from the outside; they look like the medication suddenly stopped working, or like a side effect that came out of nowhere.
A 70-year-old on simvastatin starts having coffee with grapefruit juice every morning at breakfast. Three weeks in, his legs ache walking up the stairs. He puts it down to age. By month two he can barely stand from a chair without thigh pain. His urine darkens. The hospital catches the rhabdomyolysis before kidney damage becomes permanent.
A 32-year-old on the combined pill picks up St John's wort capsules at the chemist for a low mood, doesn't mention it to her GP. Six weeks later, period is late. She's been on the same pill for years; she didn't miss any. The pregnancy is unintended.
A transplant recipient — heart, kidney, liver, doesn't matter which — adds a herbal pill from a health-food shop because someone said it would help with mood. Within a month, the immunosuppressant levels their transplant team has been carefully titrating for years are half what they were. The next blood draw shows the organ in early rejection.
A man on an SSRI for depression adds St John's wort because someone online said it stacks well with antidepressants. Within days he feels agitated, sweaty, his pulse races. He thinks the depression is getting worse and increases the SSRI. He ends up in A&E with serotonin syndrome.
The reason these go unrecognised isn't that the science is obscure — it's been in medical school curricula for two decades. It's that the food and the herbal pill don't feel like medication. A glass of juice at breakfast and a bottle from the supplements aisle aren't on the patient's mental list of "things I take." The clinician doesn't ask. The patient doesn't volunteer. The interaction does its work invisibly.
What to do
The action splits cleanly along whether you're on a CYP3A4 substrate medication or not. Most readers aren't. If you take no prescription medications, eat grapefruit freely and ignore the rest of this section. St John's wort is a separate decision (it's a real, if modest, treatment for mild depression) but doesn't carry interaction risk if there's nothing for it to interact with.
If you do take prescription medications, the protocol is short.
For the affected drug classes specifically: if you must take a statin and want grapefruit, ask your prescriber to switch you to pravastatin, rosuvastatin, fluvastatin, or pitavastatin — none go through CYP3A4 in a meaningful way. If you're on the combined contraceptive pill and want St John's wort for mild depression, the cleaner solution is to use a different antidepressant or a non-hormonal contraceptive method. The "stacking" you might have heard about — St John's wort plus a prescription SSRI — is the most dangerous combination on the list and has no legitimate evidence base.
Common mistakes
The five things most often misunderstood:
- "I'll just space the grapefruit and the pill by a few hours." Doesn't work. The grapefruit doesn't compete with the pill at absorption — it permanently disables the enzyme molecules it touches, and your body takes one to three days to rebuild them. Eating grapefruit at breakfast and taking your pill at dinner is the same exposure as taking them together.
- "It's only the juice, not the fruit." The chemicals that do the damage are in the whole fruit, especially in the peel. Marmalade made with Seville orange is grapefruit-equivalent. Pomelo and tangelo (a grapefruit hybrid) are grapefruit-equivalent. Sweet orange, mandarin, clementine, lemon, lime — not equivalent.
- "It's natural, so it's safe with my medication." The most consequential mistake in the catalogue. St John's wort has produced documented heart-transplant rejections, unintended pregnancies on the combined pill, virological failure on HIV treatment, and serotonin syndrome with prescription antidepressants. The herb being plant-derived has nothing to do with whether it interacts with prescription drugs. Caffeine is also natural and also a CYP modulator; nicotine is natural; many of the most reactive chemicals in pharmacology started as plant alkaloids.
- "A little grapefruit can't hurt." A single 200 mL glass measurably knocks down gut enzyme levels for the rest of the day Lown et al. 1997. The mechanism is not dose-and-response in the gentle way you'd hope; even small amounts disable some fraction of the enzyme, and the disabled fraction stays disabled for days.
- "My doctor would have told me." Sometimes. Often not — especially with herbal supplements, which most patients don't think of as medications and most clinicians don't think to ask about. The interaction lives in a gap between patient and prescriber. Closing that gap is the patient's job at least half the time.
Who especially needs to read this
The risk concentrates sharply in four groups.
Older adults on multiple daily medications. Polypharmacy increases the odds that one of your pills is a CYP3A4 substrate; statins, calcium-channel blockers, and several common antidepressants are top of the list. Grapefruit at breakfast is also more common in this age band. The same dose at 75 doesn't behave like the same dose at 25, and a grapefruit interaction layered on top of normal age-related slowing of drug clearance compounds quickly.
People on the combined contraceptive pill. St John's wort is sold over the counter as a mood supplement; combined hormonal contraceptives are an enormously common prescription; the two combinations are catastrophic in the small slice of cases where they fail. The risk is the failure mode that doesn't look like a failure mode — a pregnancy you didn't expect, eight weeks after starting a herbal supplement.
Transplant recipients. The narrowest therapeutic window in routine medicine. Most transplant programmes give explicit instructions; the patients who get into trouble are usually the ones who heard the instructions once at discharge and forgot. Re-read the discharge sheet. If grapefruit, pomelo, or any herbal supplement isn't on it, ask.
People taking prescription antidepressants who want to "stack" St John's wort on top. Don't. The combination has produced serotonin syndrome, and the marginal antidepressant benefit of adding a herbal SSRI to a prescription SSRI is unestablished and probably zero — they target the same system. If your prescription isn't working, the conversation is with your prescriber, not with the supplements aisle.
What you actually get from this
For most readers — the no-prescription reader — the payoff is the knowledge itself. The day a clinician hands you a new prescription and asks if you have any questions, you have one to ask. That moment, repeated over a lifetime, is a small but real piece of medical literacy that compounds.
For the reader on a daily prescription, the payoff is invisible. You don't have a transplant rejection that didn't happen. You don't have a statin-induced muscle injury that didn't happen. You don't have an unintended pregnancy that didn't happen. The wins are silent, and that's the only way you'll know it worked.
The cost side of the trade is roughly nothing. Sweet orange tastes like grapefruit's friendlier cousin. A different antidepressant — including ones that out-perform St John's wort in head-to-head trials — is one prescriber visit away. Five minutes of asking the pharmacist on each new dispense is a habit that takes two prescriptions to form.
This isn't a heroic intervention. It's the small move that turns out, in the slice of cases where it matters, to be the difference between your medication doing its job and your medication doing something else entirely.
Two adjacent topics this entry brushes past but doesn't cover. St John's wort as a treatment for mild-to-moderate depression — separately from the drug-interaction story, the Cochrane evidence is genuinely positive Linde et al. 2008, and it has its own decision worth thinking through. Polypharmacy as a broader topic — the more daily medications a person is on, the more often hidden food-and-drug or supplement-and-drug interactions stop being a quirk and start being the default. The principle generalises beyond grapefruit and St John's wort: every herbal supplement, every dietary change worth talking about, deserves a quick check against the prescription list.
- — St John's Wort can make hormonal birth control fail by clearing the hormones faster; use backup if you take both.
- — Statins are one of the big ones: grapefruit lets some of them pile up in your blood toward muscle damage. Check which statin you're on.
- — Red yeast rice is a hidden statin: grapefruit raises its levels just like it does prescription lovastatin.
- — Add piperine-boosted curcumin to the list of things that mess with CYP3A4 and your medications.
- — Some of the same narrow-margin drugs — transplant meds, blood thinners — are the ones grapefruit pushes toward toxic.
- — Grapefruit and St John's wort are the two best-known cases of a food or supplement rewriting a drug's effect.
- — Genes set how fast you clear a drug; this is the food-and-herb version of the same metabolism story.
- — The annual medication review is when to flag whether your drug list collides with grapefruit or this herb.
Substance + claimed effects
This entry covers two common dietary substances — grapefruit (and related citrus: pomelo, Seville orange, tangelo) and St. John's wort (Hypericum perforatum) — viewed through a single pharmacological lens: their opposite-direction modulation of cytochrome P450 3A4 (CYP3A4), the liver and gut enzyme responsible for first-pass metabolism of roughly half of all prescription drugs. Grapefruit's furanocoumarins (notably bergamottin and 6',7'-dihydroxybergamottin) irreversibly inhibit intestinal CYP3A4, raising plasma concentrations of affected drugs; St. John's wort's hyperforin activates the pregnane X receptor and induces hepatic and intestinal CYP3A4 (and the efflux transporter P-glycoprotein), lowering plasma concentrations Bailey 2013 Moore et al. 2000. The drug classes the description names — statins, immunosuppressants, calcium-channel blockers, hormonal contraceptives, psychotropics — share heavy CYP3A4 dependence and narrow therapeutic windows. Consequences covered here are iatrogenic harm and therapeutic failure: rhabdomyolysis from raised statin levels, acute transplant rejection from suppressed tacrolimus or cyclosporine levels, contraceptive failure with unintended pregnancy, supratherapeutic calcium-channel blocker effects (hypotension, bradycardia), and loss of antiretroviral / antidepressant / anxiolytic efficacy. The article scores against the avoidance behaviour (don't eat grapefruit / don't take SJW while on these drugs), not against the drugs themselves.
Evidence by addressing question
Mechanism
Grapefruit — irreversible inhibition of intestinal CYP3A4. The original discovery was accidental: Bailey et al. 1991 used grapefruit juice to mask the taste of ethanol in a felodipine pharmacokinetic study and found felodipine area-under-curve (AUC) tripled. The mediating compounds are furanocoumarins — bergamottin, 6',7'-dihydroxybergamottin, and bergaptol — which form covalent adducts with CYP3A4 in the enterocytes of the small intestine. Lown et al. 1997 showed that a single 8-oz glass of grapefruit juice reduced intestinal CYP3A4 protein content by ~62% on duodenal biopsy, with no change in hepatic CYP3A4 mRNA. Definitive causality was established with a furanocoumarin-free grapefruit juice trial: stripping the furanocoumarins eliminated the felodipine interaction entirely, confirming furanocoumarins as the mediators rather than flavonoids (naringin, naringenin) — a long-standing misattribution. Inhibition is mechanism-based / suicide: the enzyme is destroyed, so recovery requires de novo synthesis. Greenblatt et al. 2003 quantified recovery: ~50% of CYP3A4 activity returns within 24 h after a single dose, but full recovery takes ~72 h; a hypothesis sometimes called the "three-day rule."
St. John's wort — induction via the pregnane X receptor (PXR / NR1I2). Moore et al. 2000 demonstrated that hyperforin is one of the most potent known activators of the human PXR (EC50 ~23 nM), a nuclear receptor whose transcriptional targets include CYP3A4 (~700% induction in primary hepatocytes), CYP2C9, CYP1A2, and the efflux transporter MDR1/P-glycoprotein. Induction is slow on, slow off: enzyme upregulation requires sustained dosing (typically 10–14 days of 900 mg/day standardised extract to reach peak induction) and decays over 1–2 weeks after discontinuation, as new ribosomes catch up with normal CYP3A4 turnover. Markowitz et al. 2003 demonstrated 1.66-fold increased oral midazolam clearance after 14-day SJW dosing, the canonical CYP3A4 probe response. Critically, Mai et al. 2003 showed that the hyperforin content of the preparation drives the magnitude — low-hyperforin extracts (e.g., Ze 117) produced minimal cyclosporine effect, conventional high-hyperforin extracts produced 45% AUC reduction. This matters because SJW preparations on the supplement market are unregulated and vary 5- to 10-fold in hyperforin content.
Evidence
Statins. Grapefruit raises CYP3A4-metabolised statins (simvastatin, lovastatin, atorvastatin) and does not raise CYP3A4-independent statins (pravastatin, rosuvastatin, fluvastatin). Lilja et al. 1998: 200 mL grapefruit juice three times daily for three days increased simvastatin AUC by ~16-fold (active acid metabolite +7-fold). Lilja et al. 1999: atorvastatin AUC +83% under similar conditions; pravastatin unchanged. The downstream signal is rhabdomyolysis: case reports cluster around simvastatin and lovastatin co-consumed with chronic grapefruit. SJW induces statin metabolism in the opposite direction — simvastatin AUC reduced ~62% by 14-day SJW co-administration Mannel 2004.
Immunosuppressants — the highest-stakes category. Cyclosporine and tacrolimus have narrow therapeutic windows (cyclosporine target 100–300 ng/mL trough), are heavily CYP3A4-dependent, and also rely on P-glycoprotein. Ruschitzka et al. 2000 reported two cases of acute heart transplant rejection after patients began self-medicating with St. John's wort; cyclosporine trough levels fell 50% within weeks. Hojo et al. 2011 and Mai et al. 2003 quantified the cyclosporine AUC drop and confirmed hyperforin-dose-dependence. Conversely, grapefruit can elevate cyclosporine/tacrolimus; though some early thinking explored grapefruit as an intentional cyclosporine-sparing strategy, the variable magnitude of effect made it clinically unworkable.
Calcium-channel blockers. Felodipine is the canonical case: Bailey et al. 1991 and many replications show 2–3× AUC increase from one glass of grapefruit juice, with measurable hypotension and reflex tachycardia. Lundahl et al. 1995 demonstrated the effect persists when grapefruit is consumed 24 h before felodipine — confirming the irreversible inhibition mechanism. Lundahl et al. 1997 showed the inhibition is maximal after the first glass — chronic exposure adds no additional inhibition, but a single intake is enough. Nifedipine, nisoldipine, and amlodipine are also CYP3A4-dependent though less affected than felodipine. SJW induction drops nifedipine plasma levels meaningfully though clinical consequences are less dramatic than for transplant drugs.
Hormonal contraceptives. Ethinylestradiol and progestins (norethindrone, levonorgestrel, desogestrel) are CYP3A4 substrates. Hall et al. 2003: 14-day SJW dosing reduced norethindrone AUC by 13% and increased ethinylestradiol clearance, with breakthrough bleeding in 7/12 women (vs 2/12 placebo) — a clinical signal of declining contraceptive coverage. Murphy et al. 2005 extended this: SJW increased the proportion of cycles with follicular growth (a marker of escaped ovulation suppression) and breakthrough bleeding. Schwarz et al. 2003 documented case reports of unintended pregnancy under SJW co-medication despite combined oral contraception. Grapefruit's contribution here is mostly theoretical/minor (mild AUC increase, no clinical signal of harm).
Psychotropics. Many CYP3A4-metabolised: midazolam, alprazolam, buspirone, quetiapine, aripiprazole, ziprasidone, trazodone, sertraline (partially). Grapefruit and SJW shift their plasma concentrations in opposite directions. Midazolam is the standard CYP3A4 probe in pharmacology: Greenblatt et al. 2003 documented near-doubling of oral midazolam AUC after grapefruit; Markowitz et al. 2003 documented 1.66-fold clearance increase after SJW. Serotonin syndrome is the special hazard when SJW (which has mild SSRI-like activity itself; see Linde et al. 2008) is combined with serotonergic antidepressants — a pharmacodynamic interaction added on top of the CYP3A4 induction.
Other categories worth naming. Piscitelli et al. 2000: SJW reduced indinavir (HIV protease inhibitor) AUC by 57% — the report that triggered FDA contraindication for SJW + antiretrovirals. Johne et al. 1999: SJW reduced digoxin AUC by 25% via P-gp induction (digoxin isn't a CYP3A4 substrate but the P-gp pathway runs in parallel). Schwarz et al. 2005: talinolol AUC reduced 31% by SJW, isolated P-gp effect.
Contraindications
The contraindication landscape is about the medication, not the food/herb — grapefruit and SJW are unsafe only in the context of a vulnerable co-medication. The major substrate classes the literature documents Bailey 2013 FDA 2021:
- Statins: simvastatin, lovastatin, atorvastatin (NOT pravastatin, rosuvastatin, fluvastatin)
- Calcium-channel blockers: felodipine, nifedipine, nisoldipine, amlodipine (less so)
- Immunosuppressants: cyclosporine, tacrolimus, sirolimus, everolimus
- Antiarrhythmics: amiodarone, dronedarone, quinidine
- Anticoagulants: apixaban, rivaroxaban (DOACs); warfarin (PD/PK signal)
- Antidepressants/anxiolytics: sertraline, citalopram, escitalopram, alprazolam, buspirone, quetiapine
- Hormonal contraceptives: ethinylestradiol-containing combined pills, progestin-only pills
- Antiretrovirals: indinavir, saquinavir, ritonavir, the integrase-inhibitor class
- Anti-cancer kinase inhibitors: imatinib, nilotinib, dasatinib, sunitinib, sorafenib (narrow therapeutic windows + CYP3A4 dependence)
- Erectile-dysfunction drugs: sildenafil, tadalafil (additive hypotension risk with grapefruit)
- Other narrow-window CYP3A4 substrates: colchicine (rhabdomyolysis), carbamazepine
Pregnancy and breastfeeding are independently relevant: SJW is contraindicated in pregnancy (potential abortifacient activity from hyperforin; teratogenicity data inadequate); grapefruit is not. The drug-interaction contraindications above apply across both sexes and all ages.
Protocol
The practical guidance synthesises across primary-care, pharmacy, and transplant-clinic consensus:
- Grapefruit timing. Because the inhibition is mechanism-based, spacing the food and the drug by hours does not work. Lundahl et al. 1995 demonstrated felodipine elevation persists 24 h after grapefruit; Greenblatt et al. 2003 documented 50% recovery in 24 h and full recovery only at ~72 h. The pharmacological default for affected drugs is total avoidance during therapy; the "three-day rule" (avoid for 72 h before any dose of the drug) is the practical maximum if the patient wants to eat grapefruit occasionally.
- Dose-response is shallow. Lundahl et al. 1997 showed maximal inhibition after the first 8-oz glass; bigger or more frequent intake adds little additional effect. There is no "safe small amount" — half a glass produces most of the inhibition.
- SJW washout. CYP3A4 induction decays over 1–2 weeks after discontinuation. For perioperative or peri-transplant management, the pharmacological default is to discontinue SJW ≥2 weeks before the dose-sensitive drug is started or adjusted.
- Substitute within drug class. Most affected drugs have a CYP3A4-independent alternative: pravastatin/rosuvastatin for simvastatin; loratadine for older sedating antihistamines; SNRI alternatives where psychiatric care permits. The choice belongs to the prescribing clinician.
Misconceptions
- "Only juice matters." Whole grapefruit, grapefruit segments, and grapefruit zest all carry furanocoumarins. The juice studies dominate the literature because juice standardises the dose, not because juice is uniquely active.
- "Only grapefruit." Seville (sour) orange, pomelo, and tangelo carry comparable furanocoumarin loads and produce similar inhibition. Sweet orange (Valencia, navel) does not — it lacks the relevant furanocoumarins. Lemons and limes are mild but not negligible (especially lime juice).
- "Take the drug at a different time of day." Doesn't work — see Protocol above.
- "Natural means safe." The most consequential herb-drug interaction in transplant medicine — acute organ rejection — was caused by an over-the-counter herbal supplement Ruschitzka et al. 2000. The "natural" framing is the failure mode (see below).
- "SJW dose matters more than brand." Hyperforin content varies 5- to 10-fold across products labelled with the same "300 mg standardised" extract Mai et al. 2003. The dose on the bottle does not reliably predict the induction magnitude.
- "All statins are equivalent for grapefruit." Pravastatin and rosuvastatin are CYP3A4-independent and unaffected by grapefruit.
Failure modes
- Self-medication concealment. Patients consistently fail to disclose herbal supplements to clinicians — the supplement is mentally categorised as "food" or "vitamins," not "medication." Henderson et al. 2002 documented this across spontaneous-reporting databases. The interaction surfaces as unexplained loss of efficacy: rising tacrolimus dose requirements, breakthrough seizures on carbamazepine, breakthrough bleeding on the pill.
- Pharmacist gap. Pharmacy interaction-checking software flags grapefruit on the patient information leaflet but rarely flags herbal products unless the patient enters them.
- "I only had a little." The dose-response is so shallow Lundahl et al. 1997 that intuition about "moderate consumption" is wrong. A single small intake matters; large intake does not matter more.
- Stopping SJW abruptly. Induction decays over 1–2 weeks; abrupt discontinuation in a steady-state tacrolimus patient causes rising tacrolimus levels as the induced enzyme returns to baseline. The opposite problem to the starting case but equally important.
Audience
By substrate-drug exposure:
- Solid-organ transplant recipients — highest stakes. Acute rejection on SJW is a documented fatal outcome Ruschitzka et al. 2000.
- Older adults on combination cardiovascular regimens — statin + calcium-channel blocker + DOAC together compound grapefruit risk; this population is disproportionately prescribed these classes.
- Women on hormonal contraception — SJW for premenstrual mood symptoms or depression is a common combination with contraceptive failure as a documented consequence Schwarz et al. 2003.
- People with HIV on antiretroviral therapy — the original index population for FDA SJW warnings Piscitelli et al. 2000.
- Patients on psychiatric medication — both for the CYP3A4 substrate interaction and for additive serotonergic effects from SJW.
- Cancer patients on oral kinase inhibitors — narrow therapeutic windows, CYP3A4-dependent, increasingly prevalent outpatient regimen.
Alternatives
Most affected drug classes contain at least one CYP3A4-independent member; substitution is the clinical default when grapefruit avoidance is impractical or SJW is desired:
- Statins → pravastatin, rosuvastatin, fluvastatin (CYP3A4-independent)
- Calcium-channel blockers → diltiazem, verapamil (less affected; though they have their own CYP3A4 inhibitory activity)
- Benzodiazepines → lorazepam, oxazepam, temazepam (glucuronidated, not CYP3A4)
- SSRIs → fluoxetine, paroxetine (different metabolism profile)
- Hormonal contraception under SJW → non-oral / non-systemic routes (copper IUD, depot progestin) are not rescued by SJW induction at the same magnitude
Substitution decisions are clinician-side, not patient-side; the article will frame the patient action as raise the question rather than change the prescription.
Credibility range
Optimist case (for the warning). The grapefruit and SJW interactions are some of the best-characterised drug-food/drug-herb interactions in clinical pharmacology. Mechanism is settled at the molecular level (furanocoumarins forming covalent adducts with CYP3A4; hyperforin activating PXR). Multiple human pharmacokinetic trials, with dose-response data and named-substrate clearance numbers, support the magnitude estimates. Case-series evidence covers the rare clinical consequences (rhabdomyolysis, transplant rejection, contraceptive failure). FDA labelling, transplant-society guidelines, and pharmacology textbooks converge. The intervention — avoidance, or substitution within drug class — is cheap, reversible, and low-effort.
Skeptic case. Most healthy adults take none of the affected drugs and the warning is irrelevant to them. For patients on affected drugs, the clinically reported events (rhabdomyolysis, rejection, breakthrough bleeding) are case reports, not rate estimates — population-level harm magnitude is not well quantified. The grapefruit-statin signal is dose-dependent and may be modest for low-dose simvastatin in occasional grapefruit consumers. The "three-day rule" is a conservative pharmacology heuristic, not a tested clinical recommendation. SJW preparations vary 5- to 10-fold in hyperforin content, so blanket "SJW is dangerous" warnings overgeneralise; low-hyperforin preparations cause minimal interaction Mai et al. 2003. Some interaction warnings on patient leaflets are theoretical rather than clinically documented.
Author's call. The mechanism, magnitude, and direction of these interactions are not in dispute — this is settled CYP3A4 pharmacology with consistent replication. The honest framing for a reference catalogue is: high confidence in the existence and direction of the interactions; less confidence in the rate of catastrophic outcomes at the population level; very high confidence that affected-population harms (rejection, rhabdomyolysis, pregnancy) are real and avoidable. The right reader action is awareness and disclosure to a prescribing clinician — not panic about a single grapefruit slice. Evidence score 5 (settled mechanism, multiple RCTs); controversy score 1 (minor ongoing debate about hyperforin-content cutoffs and clinical magnitude in low-risk substrate use).
Stakeholder + incentive map
- Pharmacovigilance / regulatory: FDA, EMA, MHRA. Strong push to label CYP3A4 substrates with grapefruit and SJW warnings; the labelling is uniform and conservative.
- Transplant clinicians: The community most attuned to the SJW interaction (and to grapefruit avoidance for tacrolimus/cyclosporine). Universally counsel avoidance of both.
- Herbal supplement industry: Commercial incentive to downplay interaction risk. SJW is sold as a "natural antidepressant" with disclaimers that vary by jurisdiction; in Germany SJW is a prescription pharmaceutical, in the US it is OTC. The Cochrane SJW review Linde et al. 2008 finds the herb has modest antidepressant efficacy comparable to SSRIs in mild-moderate depression — this is real, and not in conflict with the interaction warning.
- Grapefruit growers / juice industry: Smaller commercial pushback; industry-funded work has explored low-furanocoumarin grapefruit cultivars and processing methods.
- Pharmacology academic community: The Bailey group at Western Ontario is the dominant source for grapefruit-interaction research; SJW research is more distributed.
- Pharmacists at point-of-dispensing: The recurring backstop. Grapefruit warnings reliably surface on the patient leaflet; SJW warnings depend on the patient mentioning the supplement.
Population variability
- Baseline CYP3A4 expression varies ~10-fold between individuals. Patients with lower baseline intestinal CYP3A4 (genetic, age-related, or already pharmacologically inhibited) experience proportionally larger relative inhibition from grapefruit. Pharmacogenomic CYP3A4/5 polymorphisms add another layer of variability.
- Older adults have higher exposure on average because they take more CYP3A4 substrates (statins, calcium-channel blockers, DOACs) and have lower baseline CYP3A4 reserve.
- Women on combined hormonal contraception have CYP3A4 baseline depressed by ethinylestradiol, raising relative sensitivity to grapefruit interactions with co-medications; the same baseline depression makes ethinylestradiol itself more sensitive to SJW induction.
- Pediatric population — interactions extrapolated from adult data; less direct evidence. Less commonly an issue because affected drug classes are less prescribed.
- Severe hepatic impairment alters CYP3A4 function unpredictably; effect of grapefruit/SJW is harder to predict.
Knowledge gaps
The most important uncertainty is population-level event rates: how often does grapefruit consumption in real-world statin users cause clinically meaningful rhabdomyolysis? How often does SJW co-medication cause contraceptive failure in real-world OCP users? Pharmacokinetic data are abundant; outcome-incidence data are sparse and come mostly from case reports and pharmacovigilance signals. A second gap is whether low-hyperforin SJW preparations (such as Ze 117) are safe enough to be the default — preliminary evidence says yes but the supplement market does not distinguish them. A third is whether furanocoumarin-free grapefruit cultivars can be commercialised at scale; the Paine et al. 2006 paper proved the concept but commercial uptake is minimal. Finally, the interaction profile of newer kinase inhibitors and oral oncology drugs is being mapped in parallel with their approval — a moving target rather than a settled domain.
Scope. The brief named the substance (CYP3A4 modulation by grapefruit and St John's wort) and five drug classes (statins, immunosuppressants, calcium-channel blockers, hormonal contraceptives, psychotropics). The article covers all five end-to-end in the evidence section. Additional affected classes (DOACs, warfarin, antiretrovirals, ED drugs, amiodarone) get a brief signpost rather than full treatment — they would dilute the five-class story and most are clinician-managed rather than patient-action-relevant.
One entry, two substances. Grapefruit and St John's wort have nothing in common chemically or culturally; pairing them in one entry is justified only by the shared mechanism (CYP3A4 modulation). The risk of doing this is that the entry feels like two articles awkwardly fused. Mitigation: the mechanism section frames them as mirror images from the start, and every drug-class subsection in §evidence handles both directions. If this entry ever needs to split, the natural cut is by substance (grapefruit-CYP3A4-inhibition, st-johns-wort-CYP3A4-induction), not by drug class.
Rating difficulty: short-term health. Scored 3 on health_short_term, which is high for an entry whose action is "avoid two specific dietary items." The score reflects the substance's protective magnitude in the at-risk population (someone on simvastatin avoiding rhabdomyolysis is a meaningful near-term health win), not the broad reader for whom the entry is informational only. Alternative was scoring 1 or 2 to reflect the small affected fraction; rejected because the rating framework says score the substance, not the article's coverage. Same logic for longevity at 2.
Zero scores on energy / focus / sleep / mood / beauty. No direct effect on any of these from either substance considered as a CYP3A4 modulator. St John's wort has its own mood effect when used as an antidepressant, but that's a different entry — including the mood effect here would conflate the interaction story with the treatment story. Flagged in editor notes as a future-link.
Category. Placed under medical rather than food or supplements. The entry's centre of gravity is pharmacology — a drug interaction warning — not the nutritional profile of grapefruit or the herbal-supplement landscape. A reader looking for grapefruit-as-food or St John's wort-as-antidepressant should find separate future entries.
Action verb. Chose avoid over know. know would have been defensible (the entry is informational for the majority of readers) but avoid matches the substantive action the affected subgroup needs to take, and the article's protocol section makes that the centre of the recommendation.
Future-link candidates.
- st-johns-wort-for-depression — the same herb, evaluated as a mild-to-moderate depression treatment. The Cochrane evidence (Linde et al. 2008) is genuinely positive; the topic deserves its own entry rather than a footnote here.
- polypharmacy-and-supplement-disclosure — the generalised principle: every herbal supplement, every dietary change deserves a check against the prescription list. Grapefruit and St John's wort are the most-cited examples, not the only ones.
- simvastatin-vs-rosuvastatin or a broader statin-choice entry — the CYP3A4-substrate distinction is one of several axes on which statins differ.
- transplant-medication-basics — narrow audience but very high stakes; this entry signposts the issue but doesn't carry full transplant-pharmacy detail.
Hard decision: the rhabdomyolysis numbers. The 16-fold simvastatin AUC figure from Lilja et al. 1998 is the most-cited number in the grapefruit literature but came from an extreme dosing protocol (200 mL double-strength juice three times daily for three days) that doesn't match real-world consumption. Reported the number but contextualised it as the worst-case ceiling rather than the typical exposure. The intermediate exposures (one glass at breakfast on a stable statin dose) have less rigorous data and the article doesn't pretend otherwise.
Voice tension. The substance is technical (cytochrome P450 enzymology) and the reader is mostly a layperson trying to figure out if their breakfast is a problem. Tried to keep the mechanism section in plain-language analogies (enzyme "chewing up" the drug) and push the trial-level detail into science callouts. The friend-test bar is harder here than on most entries because the topic naturally pulls toward textbook voice.
Grapefruit, St John's Wort, and CYP3A4
For affected patients, the lifestyle adjustment is small: skip grapefruit / Seville orange / pomelo on the breakfast menu, and disclose herbal supplements to the prescriber. No daily protocol or technique to learn.
Mechanism is established at the molecular level: furanocoumarins covalently inactivate intestinal CYP3A4 (Paine et al. 2006); hyperforin activates the pregnane X receptor to induce hepatic CYP3A4 (Moore et al. 2000). Multiple human pharmacokinetic trials with named substrates and dose-response data (Lilja et al. 1998, Bailey et al. 1991, Markowitz et al. 2003), FDA labelling, and transplant-society guidelines converge.
For people on affected medications, avoiding grapefruit and St. John's wort prevents documented near-term harms: rhabdomyolysis from simvastatin/atorvastatin (Lilja et al. 1998, 1999), supratherapeutic calcium-channel blocker effects, and breakthrough bleeding on hormonal contraception (Hall et al. 2003). The benefit is felt as 'nothing goes wrong' — the absence of a class of avoidable adverse events.
For transplant recipients, avoiding St. John's wort prevents acute organ rejection — a documented fatal outcome (Ruschitzka et al. 2000). For statin users, avoiding grapefruit prevents rhabdomyolysis. Population magnitude is modest because only a fraction of readers carry the relevant prescriptions, but the avoided events are mortality-relevant for that subgroup.